MS/AL Radiation Oncology Research Partnership W. Sam Dennis, MD, PhD P.I., Singing River Hospital System Sharon Spencer, MD P.I., University of Alabama.

Slides:



Advertisements
Similar presentations
San Antonio Breast Cancer Symposia Authors: Dr. Sunil Verma Date posted: January 6 th, 2008.
Advertisements

American Cancer Society Patient Resource Navigation Program Brandon Costantino University of Maryland Medical Center.
Xeloda X-panding options in the adjuvant treatment of breast cancer
Gynecologic Oncology Group Gynecologic Oncology Group Uterine Corpus Trials: GCIG David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
MMC Cancer Institute Navigation Program Donna Green BSN, RN,BA,OCN
Advocating for Clinical Trial Accural
Michael Birrer, PI, Director, Gynecologic Medical Oncology, MGH Lari Wenzel, Co-PI, Prof. of Medicine, University of California, Irvine
NSABP PROTOCOL C-10: RESULTS A Phase II Trial of 5-Fluorouracil, Leucovorin and Oxaliplatin (mFOLFOX6) Plus Bevacizumab for Patients with Unresectable.
Cancer Disparities Research Partnership Program Process & Outcome Evaluation Amanda Greene, PhD, MPH, RN Paul Young, MBA, MPH Natalie Stultz, MS NOVA Research.
Herceptin® (trastuzumab) in combination with chemotherapy: pivotal metastatic breast cancer survival data 1.
Memorial Sloan-Kettering Cancer Center
Cancer Clinical Trials:
Clinical Trials The Way We Make Progress Against Disease.
Academic & Community Cancer Research United (ACCRU) Scientific Achievements.
BIOLOGICAL PRINCIPLES OF BREAST CANCER TREAMENT Benjamin O. Anderson, M.D. Director, Breast Health Clinic Professor of Surgery and Global Health, University.
Cancer Center Trials at St. Barnabas Medical Center.
Wrexham Maelor Lung Clinical Trials Overview February 2008.
Intra-Operative Radiation Therapy for Treatment of Early Stage Breast Cancer: Short Term Results from a Single Institution Clinical Trial Using Electronic.
Colorectal Cancer Center Jena Introduction In Germany, there are currently approximately newly diagnosed patients with colorectal carcinoma.
Breast Cancer Clinical Cases Daniel A. Nikcevich, MD, PhD SMDC Cancer Center April 20, 2009.
ACRIN Research Associates Educational Session Radiation Therapy Oncology Group Research Associates Committee Joyce Neading, RHIT, CTR Program Director,
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Vascular issues associated with bevacizumab Stuart M. Lichtman, MD, FACP 65+ Clinical Geriatric Program Associate Attending Memorial Sloan-Kettering Cancer.
First Safety Data from a Randomized Phase III (CIBOMA/ /GEICAM ) Trial Assessing Adjuvant Capecitabine Maintenance Therapy After Standard.
Patterns of Care in Medical Oncology Neoadjuvant and Adjuvant Treatment of Rectal Cancer.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
1 The Cancer Consortium Deborah Schrag, MD (PI) Caprice Christian Greenberg, MD, MPH Brigham and Women’s Hospital Dana-Farber Cancer Institute.
Clinical Trials that Address Health Care Disparities Daniel G. Petereit, MD Department of Radiation Oncology University of Wisconsin Medical School University.
ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.
1 Targeted Strategies to Improve Physician and Patient Access to Cancer Clinical Research An Overview of Coalition Programs and Services Ruth Lambersky.
Taxane-pretreated metastatic breast cancer (MBC): investigational agents TTP = median time to disease progression OS = median overall survival.
Adjuvant Therapy of Colon Cancer 2005 Daniel G. Haller, M.D. Abramson Cancer Center at the University of Pennsylvania Philadelphia PA.
Patterns of Care in Medical Oncology Adjuvant Systemic Therapy for Colon Cancer.
Is surgical resection of an asymptomatic primary colorectal tumor beneficial for patients with incurable Stage IV disease? A Phase II Trial of 5-Fluorouracil,
The Impact of Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Patients with Carcinoma of the Rectum: NSABP R-04 1 Capecitabine.
The Colorectal Cancer Center Jena Gharbi A, Settmacher U. Department of General, Visceral and Vascular Surgery, Friedrich-Schiller-University Jena
The Cancer Trials Support Unit (CTSU) Steve Riordan, Project Director Jenny Hopkins, Task Manager CTSU/Westat, Rockville, MD June 26, 2007 Clinical Trials.
TREATMENT Mastectomy -traditionally, treatment of breast ca has been surgical -19 century, surgical treatment : local excision ~ total mastectomy : radical.
Recent Advances in Head and Neck Cancer Robert I. Haddad, M.D., and Dong M. Shin, M.D. The NEW ENGLAND JOURNAL of MEDICINE N Engl J Med 2008;359:
Chair:Dr. Vivien Bramwell NATIONAL CANCER INSTITUTE OF CANADA CLINICAL TRIALS GROUP Sarcoma Committee CANADIAN SARCOMA GROUP.
NCI-Sponsored Clinical Trials Andrea Denicoff, RN, MS, ANP 1 Worta McCaskill-Stevens, MD 2 Jo Anne Zujewski, MD 1 Jeff Abrams, MD 1 June 25, 2007 NCCCP.
Progress Report, June 2006: CDRP Grant Programs Singing River Hospital System Pascagoula, Mississippi.
Gynecologic Oncology Group Gynecologic Oncology Group (GOG) Sharon Stockman, C-CRC The University of Iowa Hospitals Iowa City, IA Chair, GOG Data Management.
Building Clinical Infrastructure and Expert Support Michael Steinberg, MD, FACR ULAAC Disparity Project Centinela/Freeman Health System.
1 National Cancer Institute Clinical Trial Cooperative Groups Perspectives from the National Surgical Adjuvant Breast and Bowel Project Joyce Mull, MPM.
Progress Report, Feb. 2007: CDRP Grant Programs Singing River Hospital System Pascagoula, Mississippi.
Istituto Nazionale per la Ricerca sul Cancro Genoa – Italy
Treatment Regimens of HER2+ Adjuvant Patients (Actuals) Source: Genentech ASCO 2005 (data release) Nov 2006 (Approval)
Cancer Disparities Research Partnership (CDRP): Linking University & Community Radiation Oncology to Improve Cancer Outcomes Patrick D. Maguire, M.D. New.
Endometrial Committee David Scott Miller, M.D., F.A.C.O.G., F.A.C.S. Director and Dallas Foundation Chair in Gynecologic Oncology Professor of Obstetrics.
Adjuvant chemotherapy – When should surgeons recommend? Joint Hospital Surgical Grand Round Dr Lorraine Chow Ruttonjee Hospital.
CDRP Steering Committee UPMC McKeesport January 20th, 2006.
Taxanes — Taxanes are among the most active agents for metastatic breast cancer – Docetaxel, Paclitaxel, NabPaclitaxel. Anthracyclines – Doxorubicin, Epirubicin,
Improving Cancer Outcomes for African-Americans New Hanover Regional Medical Center Coastal Area Health Education Center University of North Carolina at.
CDRP Program Update UPMC McKeesport Program Steering Committee RTOG Meeting Toronto, Canada June 23 rd, 2006.
The TJU Human Research Protection Program (HRPP): Part I – Which Entities/Offices are Involved ? J. Bruce Smith, MD, CIP.
NJMS-UH Cancer Center Minority- Based Community Clinical Oncology Program.
NCCCP Pilot – Clinical Trials Ann O’Mara, PhD, RN, FAAN Program Director Community Clinical Oncology Program Division of Cancer Prevention June 26, 2007.
S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients.
Agency Review of sNDA SE-006 DOXIL for Ovarian Cancer Division of Oncology Drug Products Office of Drug Evaluation 1 Center for Drug Evaluation.
Treatment Options for Postmenopausal Women With Early-Stage Hormone Receptor–Positive Breast Cancer Recent Trials and Future Directions Harold Burstein,
Complete pathologic responses in the primary of rectal or colon cancer treated with FOLFOX without radiation A. Cercek, M. R. Weiser, K. A. Goodman, D.
BRITTANY HAGEN BS RN OCN CCRC CLINICAL RESEARCH MANAGER OHC, INC. OHC Research.
Saint Alphonsus Research Assets and Opportunities Timothy E. Sawyer, MD Radiation Oncologist Medical Director, Saint Alphonsus Cancer Care Center Founder,
CCO Independent Conference Highlights
Bozeman Health Clinical Research
No F in FEC?.
Alan P. Venook, MD University of California, SF
Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) +/- cetuximab for patients with untreated metastatic adenocarcinoma of the.
Presentation transcript:

MS/AL Radiation Oncology Research Partnership W. Sam Dennis, MD, PhD P.I., Singing River Hospital System Sharon Spencer, MD P.I., University of Alabama – Birmingham Maggie Clarkson, RN, MS Grants Program Director, Singing River Hospital System

MS/AL RADIATION THERAPY RESEARCH PROGRAM STAFFING PLAN SRHCCUABCCC P.I. – Dennis (10%) P.I. - Spencer CO – P.I.GRANTS ADMIN (.5 FTE)PROGRAM DIRECTOR (1 FTE) Clarkson (3%) Hull (3%) Sariego (2.5%) Lyell (2.5%)RESEARCH STAFFOUTREACH STAFF (*)PATIENT NAVIGATORS Research Nurse (1 FTE)Health Educator/RN (1 FTE)Patient Advocate/Van Driver (2 FTE) Data Manager(1 FTE) CONTRACT: $ /year * Shared oversight with Director, Community and Corporate Wellness Program

Partnership/Mentor Relationship Program Steering Committee Scientific Review Committee TeleSynergy programs Investigator-initiated Studies Workshops for investigators and grant staff Medical and Support Staff training opportunities

Clinical Research Development of Activation Prioritization List for Cooperative Group Studies: RTOG, SWOG, NSABP, GOG, CTSU –Patient Population Data for SRHS-RCC reviewed against Active studies listings for study groups and: Scientific questions of interest for medical staff Standard treatment remains sub-optimal for site/stage Treatment regimens inclusive of RT Annual Accrual Goals Long-term Clinical Research Office Goals

SINGING RIVER HOPSITAL REGIONAL CANCER CENTER – OPEN CLINICAL TRIALS LIST ANAL/RECTAL RTOG 0315A Randomized Double Blind Placebo-controlled Phase III Study to Determine the Efficacy of Sandostatin Lar Depot (Octreotide Acetate) in Preventing or Reducing the Severity of Chemoradiation-Induced Diarrhea in Patients with Anal or Rectal Cancer. (IRB ok 9/20/05) BREAST NSABP B-35A Clinical Trial Comparing Anastrozole with Tamoxifen in Postmenopausal Patients with Ductal Carcinoma In Situ (DCIS) Undergoing Lumpectomy with Radiation Therapy (IRB ok 4/12/06) NSABP B-36A Clinical Trial of Adjuvant Therapy Comparing Six Cycles of 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC) to Four Cycles of Adriamycin and Cyclophosphamide (AC) in Patients with Node-negative Breast Cancer (IRB ok 10/11/05) NSABP B-38A Phase III, Adjuvant Trial Coparing Three Chemotherapy Regimens in Women with Node-positive Breast Cancer: Docetaxel/Doxorubicin/Cyclophosphamide (TAC); Dose-dense (DD) Doxorubicin/Cyclophosphamide followed by DD Paclitaxel (DD AC→P); DD AC Followed by DD Paclitaxel Plus Gemcitabine (DD AC→PG) (IRB ok 10/11/05) SWOG S0221Phase III Trial of Continuous Schedule AC + G vs. Every 2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-operative Adjuvant Therapy in Node-positive or High-risk Node-negative Breast Cancer (IRB ok 10/11/05) COLON NSABP C08A Phase III Clinical Trial Comparing Infusional 5-Fluorouracil (5-FU), Leucovorin and Oxaliplatin (mFOLFOX6) every Two Weeks with Bevacizumab to the Same Regimen without Bevacizumab for the Treatment of Patients with Resected Stages II and III Carcinoma of the Colon. (IRB ok 9/20/05) LUNG SWOG S9925SWOG S9925Lung Cancer Specimen Repository Protocol, Ancillary (IRB ok 10/11/05) PROSTATE RTOG 0126A Phase III Randomized Study of High Dose 3D-CRT/IMRT versus Standard Dose 3D-CRT/IMRT in Patients Treated for Localized Prostate Cancer (IRB ok 9/20/05)

Investigator-Initiated Studies Phase I/II Trial of Alternative Dose Schedule of 1650cGy in 3 fractions for Palliative Radiation treatment of Bone Metastases Development of Geriatric Assessment Profile to Support Accrual of Elderly Patients onto Clinical Research Trials Impact of Cancer Screening Recruitment Model using Prior Participants as Advocates Among Minorities ?? Immobilization Methods for Prostate IMRT ?? Geriatric Oncology Issues

Community Involvement Focus Internal –Community & Corporate Wellness –Pharmacy/Social Services/Dietary/PT/OT/Financial Services –Transportation External –Health-related Organizations –Faith-based Organizations –Business/Corporate –Civic/Community Service Organizations –Educational Institutions Medical Community –Focus on Clinical Research Issues –Cancer Center referral base

Patient Navigator Services Team approach with oncologist/RN –Involvement post-treatment planning Supportive needs assessments –Document categories of needs –Referrals to internal/external resources Transportation assistance using van Assist with Community Outreach programs Monitor outcomes

Community Outreach Focus on minorities and underserved Develop cancer control education/awareness/screening activities appropriate to specific target populations Develop outcomes measures/monitoring methods to determine impact on participation in risk reduction activities Develop ongoing cancer patient education programs and services for SRHS Facilitate/coordinate support group activities Support development of patient advocacy program

Impact of Hurricane Katrina on Our Community: The Good, The Bad, the Ugly